Several clinical trials have been conducted to evaluate the safety and effciacy of MSC therapy for COVID-19. Studies showed that ACE2- MSCs could be beneficial for the patients with COVID-19 pneumonia (Leng et al., 2020; Zhao, 2020). Due to the fact that CAStem (Human embryonic stem ...
DRUG therapyCOVID-19HEALTH facilitiesAZITHROMYCINBackground: The COVID-19 pandemic has led to dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. The availability of a...
BEIJING, Feb. 21 (Xinhua) -- China has been advancing research on drugs and therapies against the novel coronavirus disease (COVID-19), a Chinese official said on Friday. Convalescent plasma therapy has proved to be effective on severe COVID-19 cases, said Xu Nanping, vice minister of scie...
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or human proteins to control viral infection, encompassing h
only for COVID-19, but also in future pandemics. Lessons can be drawn from successful development of antivirals against other viruses such as HIV and hepatitis C. As with those viruses, combinations of antivirals may be needed for the most effective therapy and to avoid development of ...
China has initiated several clinical research programs on stem cell therapy against COVID-19, including a stem cell drug that has been approved for clinical trial and a mesenchymal stem cell therapy. Stem cell therapy has been used to treat 64 patients in severe and critical condition. Those pa...
To date, there are no specific vaccines or antiviral drugs against COVID-19. For the treatment of patients, isolation and symptomatic supportive care are currently recommended, including oxygen therapy, water, and dielectric balance, nutritional interventions and fluid management to reduce symptoms and...
Table 1. Potential therapies for COVID-19. Drug/Therapy/VaccineClassificationFunctionClinical trialPMID Human target-based therapy Colchicine Anti-inflammatory drug Inactivates pro-inflammatory cytokines IL-1β, IL-6, and IL-18, NLRP3 inflammasome and migration of leukocytes. Phase III NCT04322682 NCT...
In clinical trials of hospitalized patients with COVID-19, Actemra in addition to the routine care patients receive for treatment of COVID-19, which included corticosteroid therapy, was shown to reduce the risk of death through 28 days of follow-up and decrease the amount of time patients ...
of this combination therapy represents an incremental step forward in the treatment ofCOVID-19in hospitalized patients, and FDA's first authorization of a drug that acts on the inflammation pathway," said Patrizia Cavazzoni, MD, acting director of the FDA's Center for Drug Evaluation and ...